Involvement of P-glycoprotein and MMP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells

Takamitsu Okada, Kazuhiro Tanaka, Fumihiko Nakatani, Riku Sakimura, Tomoya Matsunobu, Xu Li, Masuo Hanada, Tomoyuki Nakamura, Yoshinao Oda, Masazutni Tsuneyoshi, Yukihide Iwamoto

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Despite recent improvements in multimodal therapies for osteosarcoma (OS) and Ewing's family of tumors (EFTs), the prognosis of relapsed cases remains very poor because of the resistance to chemotherapy. Histone deacetylase inhibitors (HDACIs), including members of the cyclic tetrapeptide family such as FK228 and apicidin, are novel antitumor agents that can induce cell cycle arrest and apoptosis in various cancer cells. HDACIs also exhibit potent antitumor effects on OS and EFTs. However, to date there have been no studies to our knowledge reporting the effects of HDACIs on drug-resistant OS and EFTs. Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. A P-gp inhibitor (verapamil) and an MRP1 inhibitor (MK571) could independently reverse the resistance to FK228 and apicidin in the drug-resistant clones. Moreover, the combination of verapamil and MK571 could enhance HDACI-induced cell number reduction in drug-resistant clones to a similar extent as that in their parental clones. Although these findings suggest the difficulty in treating drug-resistant tumors expressing P-gp and/or MRP1 with these HDACIs, the combination of P-gp and MRP1 inhibitors might reverse the resistance to the HDACIs in the treatment of those tumors. Because HDACIs are potent and promising antitumor drugs and seem to be close to clinical use, it is necessary to pay attention to the resistance mechanisms against HDACIs.

Original languageEnglish
Pages (from-to)90-97
Number of pages8
JournalInternational Journal of Cancer
Volume118
Issue number1
DOIs
Publication statusPublished - Jan 1 2006

Fingerprint

Ewing's Sarcoma
Histone Deacetylase Inhibitors
P-Glycoprotein
Osteosarcoma
Pharmaceutical Preparations
Clone Cells
Verapamil
Antineoplastic Agents
Neoplasms
Cell Cycle Checkpoints
Doxorubicin
Cell Count
multidrug resistance-associated protein 1
Apoptosis
Drug Therapy
apicidin
romidepsin
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Involvement of P-glycoprotein and MMP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. / Okada, Takamitsu; Tanaka, Kazuhiro; Nakatani, Fumihiko; Sakimura, Riku; Matsunobu, Tomoya; Li, Xu; Hanada, Masuo; Nakamura, Tomoyuki; Oda, Yoshinao; Tsuneyoshi, Masazutni; Iwamoto, Yukihide.

In: International Journal of Cancer, Vol. 118, No. 1, 01.01.2006, p. 90-97.

Research output: Contribution to journalArticle

Okada, Takamitsu ; Tanaka, Kazuhiro ; Nakatani, Fumihiko ; Sakimura, Riku ; Matsunobu, Tomoya ; Li, Xu ; Hanada, Masuo ; Nakamura, Tomoyuki ; Oda, Yoshinao ; Tsuneyoshi, Masazutni ; Iwamoto, Yukihide. / Involvement of P-glycoprotein and MMP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. In: International Journal of Cancer. 2006 ; Vol. 118, No. 1. pp. 90-97.
@article{438474633ad8416aaa5796096ccf1a07,
title = "Involvement of P-glycoprotein and MMP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells",
abstract = "Despite recent improvements in multimodal therapies for osteosarcoma (OS) and Ewing's family of tumors (EFTs), the prognosis of relapsed cases remains very poor because of the resistance to chemotherapy. Histone deacetylase inhibitors (HDACIs), including members of the cyclic tetrapeptide family such as FK228 and apicidin, are novel antitumor agents that can induce cell cycle arrest and apoptosis in various cancer cells. HDACIs also exhibit potent antitumor effects on OS and EFTs. However, to date there have been no studies to our knowledge reporting the effects of HDACIs on drug-resistant OS and EFTs. Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. A P-gp inhibitor (verapamil) and an MRP1 inhibitor (MK571) could independently reverse the resistance to FK228 and apicidin in the drug-resistant clones. Moreover, the combination of verapamil and MK571 could enhance HDACI-induced cell number reduction in drug-resistant clones to a similar extent as that in their parental clones. Although these findings suggest the difficulty in treating drug-resistant tumors expressing P-gp and/or MRP1 with these HDACIs, the combination of P-gp and MRP1 inhibitors might reverse the resistance to the HDACIs in the treatment of those tumors. Because HDACIs are potent and promising antitumor drugs and seem to be close to clinical use, it is necessary to pay attention to the resistance mechanisms against HDACIs.",
author = "Takamitsu Okada and Kazuhiro Tanaka and Fumihiko Nakatani and Riku Sakimura and Tomoya Matsunobu and Xu Li and Masuo Hanada and Tomoyuki Nakamura and Yoshinao Oda and Masazutni Tsuneyoshi and Yukihide Iwamoto",
year = "2006",
month = "1",
day = "1",
doi = "10.1002/ijc.21297",
language = "English",
volume = "118",
pages = "90--97",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Involvement of P-glycoprotein and MMP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells

AU - Okada, Takamitsu

AU - Tanaka, Kazuhiro

AU - Nakatani, Fumihiko

AU - Sakimura, Riku

AU - Matsunobu, Tomoya

AU - Li, Xu

AU - Hanada, Masuo

AU - Nakamura, Tomoyuki

AU - Oda, Yoshinao

AU - Tsuneyoshi, Masazutni

AU - Iwamoto, Yukihide

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Despite recent improvements in multimodal therapies for osteosarcoma (OS) and Ewing's family of tumors (EFTs), the prognosis of relapsed cases remains very poor because of the resistance to chemotherapy. Histone deacetylase inhibitors (HDACIs), including members of the cyclic tetrapeptide family such as FK228 and apicidin, are novel antitumor agents that can induce cell cycle arrest and apoptosis in various cancer cells. HDACIs also exhibit potent antitumor effects on OS and EFTs. However, to date there have been no studies to our knowledge reporting the effects of HDACIs on drug-resistant OS and EFTs. Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. A P-gp inhibitor (verapamil) and an MRP1 inhibitor (MK571) could independently reverse the resistance to FK228 and apicidin in the drug-resistant clones. Moreover, the combination of verapamil and MK571 could enhance HDACI-induced cell number reduction in drug-resistant clones to a similar extent as that in their parental clones. Although these findings suggest the difficulty in treating drug-resistant tumors expressing P-gp and/or MRP1 with these HDACIs, the combination of P-gp and MRP1 inhibitors might reverse the resistance to the HDACIs in the treatment of those tumors. Because HDACIs are potent and promising antitumor drugs and seem to be close to clinical use, it is necessary to pay attention to the resistance mechanisms against HDACIs.

AB - Despite recent improvements in multimodal therapies for osteosarcoma (OS) and Ewing's family of tumors (EFTs), the prognosis of relapsed cases remains very poor because of the resistance to chemotherapy. Histone deacetylase inhibitors (HDACIs), including members of the cyclic tetrapeptide family such as FK228 and apicidin, are novel antitumor agents that can induce cell cycle arrest and apoptosis in various cancer cells. HDACIs also exhibit potent antitumor effects on OS and EFTs. However, to date there have been no studies to our knowledge reporting the effects of HDACIs on drug-resistant OS and EFTs. Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. A P-gp inhibitor (verapamil) and an MRP1 inhibitor (MK571) could independently reverse the resistance to FK228 and apicidin in the drug-resistant clones. Moreover, the combination of verapamil and MK571 could enhance HDACI-induced cell number reduction in drug-resistant clones to a similar extent as that in their parental clones. Although these findings suggest the difficulty in treating drug-resistant tumors expressing P-gp and/or MRP1 with these HDACIs, the combination of P-gp and MRP1 inhibitors might reverse the resistance to the HDACIs in the treatment of those tumors. Because HDACIs are potent and promising antitumor drugs and seem to be close to clinical use, it is necessary to pay attention to the resistance mechanisms against HDACIs.

UR - http://www.scopus.com/inward/record.url?scp=27944434891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944434891&partnerID=8YFLogxK

U2 - 10.1002/ijc.21297

DO - 10.1002/ijc.21297

M3 - Article

C2 - 16049968

AN - SCOPUS:27944434891

VL - 118

SP - 90

EP - 97

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -